Chemical Structure : Elacestrant dihydrochloride
CAS No.: 1349723-93-8
Catalog No.: PC-45734Not For Human Use, Lab Use Only.
Elacestrant (RAD1901) dihydrochloride is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD).
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $198 | In stock | |
| 10 mg | $298 | In stock | |
| 25 mg | $498 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Elacestrant (RAD1901) dihydrochloride is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD).
Elacestrant (RAD1901) inhibits ERα expression in MCF-7 cells (IC50=0.6 nM).
Elacestrant (RAD1901) induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth of multiple PDX models.
| M.Wt | 531.5568 | |
| Formula | C30H40Cl2N2O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
DMSO: 17.6 mg/mL; H2O |
|
| Chemical Name/SMILES |
2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, hydrochloride (1:2), (6R)- |
|
1. Wardell SE, et al. Endocr Relat Cancer. 2015 Oct;22(5):713-24.
2. Garner F, et al. Anticancer Drugs. 2015 Oct;26(9):948-56.
3. Bihani T, et al. Clin Cancer Res. 2017 May 4. pii: clincanres.2561.2016.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright